Colette Chew

• Lead strategic planning, market development initiatives and execution, to drive therapy adoption - delivered over 20% growth year on year
• Develop and implement new product & market launch cadence - a single product that contributed to 80% of revenue
• Market assessment and go to market strategy - led to appointment of distributor and KOL support for reimbursement submission
• Provide guidance to commercial team on price & commercial offerings - starter package & service price
• Pioneer professional education platform & initiatives - total of 11 program during covid
• Strong KOL relationship management. Involved with society in driving mechanical circulatory support initiative - delivered an AP expert consensus
• Planned and executed 3 major physician engagement events with more than 30 attendees from multiple countries for each event.

Interventional Cardiology (IC) & Structural Heart, ASEAN

• Quickly adapted to changing situation & successfully lobbied for HQ support to launch alternative transaortic valve (TAVR) in Asia Pacific
• Managed entire cardiology portfolio, including calcium management, with more than 12% year on year growth
• Brand differentiation to secure a sustained 20% price premium of DES over other brands
• Leverage good understanding of market insights & KOL relationship to secure market leadership position in major countries.
• Deep understanding of advance cardiovascular therapies landscape, including regulatory, reimbursement & funding dynamics.
• Championed innovative professional education forum for emerging cardiologists
• Initiated collaboration among countries to drive best practice

Peripheral Intervention, ASEAN / Taiwan/ Hong Kong / Korea

• Responsible for market opportunity assessment and leading both local and regional market strategy planning, development and implementation
• Lead sales team training and messaging
• Identified the emerging opportunity with vascular surgeons and initiated the first BSC participation in a regional vascular surgery meeting
• This engagement sets the foundation for the sustained16% growth in the vascular surgery business
• Double the growth of the business from 8% to16% through optimization of product portfolio and physician engagement & education

Structural Heart, Asia-Pacific

• Built business from ground zero - therapy development
• Responsible for go-to-market strategy for a stroke-prevention device including market readiness assessment; performance metric tracking and measurement; budget planning and commercialization in close collaboration with global team
• Develop regional experts and establish center of excellence for best practice sharing in ASEAN, Hong Kong, Korea, Taiwan, Japan and Australia
• Successfully launched Watchman in targeted accounts to become the first left atrial appendage closure (LAAC) in the region with a market leadership position through establishing center of excellence
• Developed the first therapy development advisory board with cross-specialties to understand barriers of adoption
• Collaborated with China regulatory and medical affair team to China FDA which led to the launch of Watchman 6 months ahead of plan

ASEAN / Taiwan / Hong Kong

• Responsible for business planning and management of distributors’ performance across all business franchise
• Delivered year on year double-digit growth of all distributor markets through close collaboration with distributors and effective marketing program
• Mitigated business risk by initiating the set up of BSC Indonesia entity to hold registration and importation of products

Interventional Cardiology – South East Asia

• Responsible for overall P&L of the IC business unit, key accounts management and team development
• Consistently delivered >15% growth over prior year and maintain market leadership

• Responsible for budget planning and P&L management of the division, managing a team of16 sales and marketing members